Abstract: The present invention relates to a layered formed sheet comprising two or more formed sheets each formed from a curable composition comprising (A) an aluminosilicate source, (B) an alkaline metal hydroxide, (C) cellulose-based fibers and (D) alkali-resistant fibers other than cellulose-based fibers, in which the aluminosilicate source (A) comprises a blast furnace slag, and the content of a blast furnace slag having a specific surface area of 1000 cm2/g or more and 9000 cm2/g or less is more than 55% by mass and 90% by mass or less related to a total solid content in the curable composition.

Abstract: The present invention relates to a cured composite comprising (A) an aluminosilicate source, (B) an alkali activator and (C) alkali-resistant fibers, in which: the aluminosilicate source (A) contains a blast furnace slag, in which the content of the blast furnace slag is 40% by mass or more relative to a total solid content in the aluminosilicate source (A); the content of the alkali activator (B) is 10% by mass or less relative to a total solid content in the curable composition; and the water content in the cured composite is 10.0% by mass or less relative to a total mass of the cured composite.

Abstract: The present invention relates to a bundled yarn, comprising plural fibers integrated by a sizing agent, wherein the sizing agent is a modified polyvinyl alcohol comprising a structural unit (X) derived from an unsaturated carboxylic acid or derivative thereof in an amount of 0.1 to 10% by mole, taking the amount of all monomer units as 100% by mole, which modified polyvinyl alcohol has a saponification degree of 85% by mole or higher.

Abstract: COMPOUNDS The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: A concrete tile comprising a tile body, the tile body having an upper face hardened through non-mold shaping, a lower face hardened through mold shaping, and a side surface that includes a cut end face in at least one side of the tile body, wherein the tile body contains alkali-resistant fiber in an entire thickness thereof in a state substantially free of fiber-containing granular bodies; the alkali-resistant fibers comprise at least one member selected from the group consisting of polyvinyl alcohol-based fibers, polyethylene fibers, polypropylene fibers, acrylic fibers, and aramid fibers; and a flexural strength of a 30 mm×150 mm sized cut piece of the tile body is not less than 6 N/mm2.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: A roof tile containing fibers which satisfy the following requirements (1) to (3): (1) to have an average fiber diameter of 50 ?m or less; (2) to have an aspect ratio of 50 to 2000; and (3) to have three or less buckled portions per fiber.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: A roof tile containing fibers which satisfy the following requirements (1) to (3): (1) to have an average fiber diameter of 50 ?m or less; (2) to have an aspect ratio of 50 to 2000; and (3) to have three or less buckled portions per fiber.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: A concrete tile comprising a tile body, the tile body having an upper face hardened through non-mold shaping, a lower face hardened through mold shaping, and a side surface that includes a cut end face in at least one side of the tile body, wherein the tile body contains alkali-resistant fiber in an entire thickness thereof in a state substantially free of fiber-containing granular bodies; the alkali-resistant fibers comprise at least one member selected from the group consisting of polyvinyl alcohol-based fibers, polyethylene fibers, polypropylene fibers, acrylic fibers, and aramid fibers; and a flexural strength of a 30 mm×150 mm sized cut piece of the tile body is not less than 6 N/mm2.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.